BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 23682827)

  • 1. Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group.
    Lacayo NJ; Alonzo TA; Gayko U; Rosen DB; Westfall M; Purvis N; Putta S; Louie B; Hackett J; Cohen AC; Cesano A; Gerbing R; Ravindranath Y; Dahl GV; Gamis A; Meshinchi S
    Br J Haematol; 2013 Jul; 162(2):250-62. PubMed ID: 23682827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell signaling-based classifier predicts response to induction therapy in elderly patients with acute myeloid leukemia.
    Cesano A; Willman CL; Kopecky KJ; Gayko U; Putta S; Louie B; Westfall M; Purvis N; Spellmeyer DC; Marimpietri C; Cohen AC; Hackett J; Shi J; Walker MG; Sun Z; Paietta E; Tallman MS; Cripe LD; Atwater S; Appelbaum FR; Radich JP
    PLoS One; 2015; 10(4):e0118485. PubMed ID: 25884949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
    Rubnitz JE; Inaba H; Dahl G; Ribeiro RC; Bowman WP; Taub J; Pounds S; Razzouk BI; Lacayo NJ; Cao X; Meshinchi S; Degar B; Airewele G; Raimondi SC; Onciu M; Coustan-Smith E; Downing JR; Leung W; Pui CH; Campana D
    Lancet Oncol; 2010 Jun; 11(6):543-52. PubMed ID: 20451454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia.
    Sievers EL; Lange BJ; Alonzo TA; Gerbing RB; Bernstein ID; Smith FO; Arceci RJ; Woods WG; Loken MR
    Blood; 2003 May; 101(9):3398-406. PubMed ID: 12506020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.
    Krug U; Röllig C; Koschmieder A; Heinecke A; Sauerland MC; Schaich M; Thiede C; Kramer M; Braess J; Spiekermann K; Haferlach T; Haferlach C; Koschmieder S; Rohde C; Serve H; Wörmann B; Hiddemann W; Ehninger G; Berdel WE; Büchner T; Müller-Tidow C; ;
    Lancet; 2010 Dec; 376(9757):2000-8. PubMed ID: 21131036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.
    Büchner T; Hiddemann W; Wörmann B; Löffler H; Gassmann W; Haferlach T; Fonatsch C; Haase D; Schoch C; Hossfeld D; Lengfelder E; Aul C; Heyll A; Maschmeyer G; Ludwig WD; Sauerland MC; Heinecke A
    Blood; 1999 Jun; 93(12):4116-24. PubMed ID: 10361108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy.
    Kornblau SM; Minden MD; Rosen DB; Putta S; Cohen A; Covey T; Spellmeyer DC; Fantl WJ; Gayko U; Cesano A
    Clin Cancer Res; 2010 Jul; 16(14):3721-33. PubMed ID: 20525753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow biopsy during induction chemotherapy for acute myeloid leukaemia identifies only 50% of patients with resistant disease.
    Roberts MM; Juttner CA; To LB; Kimber RJ
    Leuk Res; 1988; 12(10):817-21. PubMed ID: 3199841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial.
    Rees JK; Gray RG; Swirsky D; Hayhoe FG
    Lancet; 1986 Nov; 2(8518):1236-41. PubMed ID: 2878130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy of adult acute myeloid leukaemia.
    Suri R; Kueh YK; Han P; Tan YO
    Ann Acad Med Singap; 1990 Mar; 19(2):175-7. PubMed ID: 2346291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group.
    Woods WG; Kobrinsky N; Buckley JD; Lee JW; Sanders J; Neudorf S; Gold S; Barnard DR; DeSwarte J; Dusenbery K; Kalousek D; Arthur DC; Lange BJ
    Blood; 1996 Jun; 87(12):4979-89. PubMed ID: 8652810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group.
    Amadori S; Testi AM; Aricò M; Comelli A; Giuliano M; Madon E; Masera G; Rondelli R; Zanesco L; Mandelli F
    J Clin Oncol; 1993 Jun; 11(6):1046-54. PubMed ID: 8501490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive timed sequential remission induction chemotherapy with high-dose cytarabine for childhood acute myeloid leukemia.
    Loeb DM; Bowers DC; Civin CI; Friedman AD
    Med Pediatr Oncol; 2001 Oct; 37(4):365-71. PubMed ID: 11568900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
    J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive induction and consolidation chemotherapy for adults and children with acute myeloid leukaemia (AML) joint AML trial 1982-1985.
    Marcus RE; Catovsky D; Prentice HG; Newland AC; Chessells JM; Stevens RF; Hann IM; Goldman JM; Hoffbrand AV; Galton DA
    Haematol Blood Transfus; 1987; 30():346-51. PubMed ID: 2442074
    [No Abstract]   [Full Text] [Related]  

  • 16. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
    Kimby E; Nygren P; Glimelius B;
    Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intensification of chemotherapy of acute myeloid leukemia in children: report on the studies of the AML-BFM 78 and AML-BFM 83 protocols].
    Creutzig U; Ritter I; Schellong G
    Gematol Transfuziol; 1991 Jan; 36(1):16-21. PubMed ID: 2065939
    [No Abstract]   [Full Text] [Related]  

  • 18. BH3 profiling discriminates response to cytarabine-based treatment of acute myelogenous leukemia.
    Pierceall WE; Kornblau SM; Carlson NE; Huang X; Blake N; Lena R; Elashoff M; Konopleva M; Cardone MH; Andreeff M
    Mol Cancer Ther; 2013 Dec; 12(12):2940-9. PubMed ID: 24092807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of the Italian AIEOP/LAM 8204 study for the treatment of childhood AML: an update.
    Amadori S; Mandelli F; Ceci A; Comelli A; Madon E; Masera G; Nespoli L; Paolucci G; Zanesco L; Defazio D
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():114-5. PubMed ID: 2653484
    [No Abstract]   [Full Text] [Related]  

  • 20. Etoposide in remission induction of adult acute myeloid leukemia.
    Leoni F; Ciolli S; Patriarchi S; Morfini M; Rossi Ferrini P
    Acta Haematol; 1990; 83(2):82-5. PubMed ID: 2106200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.